Allergen Immunotherapy
Probelte Pharma S.L. focuses on allergen immunotherapy for allergic rhinoconjunctivitis, with research centered on grass pollen and house dust mite sensitisation. Its clinical programme includes subcutaneous immunotherapy approaches for patients with respiratory allergy symptoms linked to environmental allergens.
- Grass pollen allergy
- House dust mite allergy
- Allergic rhinoconjunctivitis
The sponsor’s trials also address patients with allergic rhinoconjunctivitis associated with asthma, reflecting interest in upper and lower airway allergic disease.
Respiratory Allergy
Clinical research activity includes treatment of allergic rhinitis and allergic conjunctivitis caused by inhaled allergens, with emphasis on symptom control in seasonal and perennial disease. The studies are designed around patients affected by exposure to pollen grasses and indoor allergens.
- Allergic rhinitis
- Allergic conjunctivitis
- Environmental allergen exposure
This area includes evaluation of immunotherapy in individuals with persistent nasal and ocular allergy symptoms, supporting research in common respiratory allergy conditions.
Polymerized Allergen Extracts
The sponsor investigates polymerized allergen extracts as therapeutic tools in allergy care, particularly formulations derived from grass pollen mixtures and house dust mite mixtures. These studies reflect a strong interest in allergen-specific treatment strategies.
- Polymerized grass pollen extract
- Polymerized house dust mite extract
- Allergen-specific treatment
Research activity in this field is directed toward improving management of sensitisation-driven disease through targeted immunological intervention.
